Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.
about
Variation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax RelapsesAge, Weight, and CYP2D6 Genotype Are Major Determinants of Primaquine Pharmacokinetics in African Children.Molecular and immunological analyses of confirmed Plasmodium vivax relapse episodesPre-clinical evaluation of CYP 2D6 dependent drug-drug interactions between primaquine and SSRI/SNRI antidepressants.Management of relapsing Plasmodium vivax malariaCytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei.Interactions between tafenoquine and artemisinin-combination therapy partner drug in asexual and sexual stage Plasmodium falciparumThe blood schizonticidal activity of tafenoquine makes an essential contribution to its prophylactic efficacy in nonimmune subjects at the intended dose (200 mg).Single dose treatment of malaria - current status and perspectives.Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: Two open-label, randomized, safety trials.CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study.Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria.Drugs in Development for Malaria.Mathematical modelling of the impact of expanding levels of malaria control interventions on Plasmodium vivaxComparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria
P2860
Q28553162-F8015CF3-B4ED-4EE0-B0EC-04E072109168Q33601837-7619FE01-ABF0-4C4D-9249-5DBB1F2A0E6CQ33743556-8AC9442B-F00A-41F0-A7E0-1F36077E2DCEQ36907360-18481940-6057-4F33-A2FD-C20573027401Q37290599-A775A507-B61D-4EA7-9B80-CF841001712FQ37480757-E9B9398D-CF5C-498C-9E4F-7A6C29410BD1Q37712176-1DFA1E39-CCC0-47D9-A17B-10CA37179760Q38774112-E3C019E1-8BEF-4E81-B113-261163876494Q39253978-58B2D7CA-E8EB-4699-B29D-36AA988C4625Q48021707-8252220A-264A-42F5-9128-E77DF68EDC92Q48024046-7E8B91C2-3B00-4D3B-9014-B75C85837C58Q55212289-4D4B19EE-D3AB-478D-B7E4-991FEF98883BQ55278895-1026627A-59BA-45D3-8157-85A00E2C8DABQ56342188-DEA8EC02-3737-4ED9-BF15-137783165D50Q56363393-18711B71-EBAD-474B-ADAD-9ADFA1626797
P2860
Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Tafenoquine treatment of Plasm ...... the Phase 2b DETECTIVE trial.
@ast
Tafenoquine treatment of Plasm ...... the Phase 2b DETECTIVE trial.
@en
type
label
Tafenoquine treatment of Plasm ...... the Phase 2b DETECTIVE trial.
@ast
Tafenoquine treatment of Plasm ...... the Phase 2b DETECTIVE trial.
@en
prefLabel
Tafenoquine treatment of Plasm ...... the Phase 2b DETECTIVE trial.
@ast
Tafenoquine treatment of Plasm ...... the Phase 2b DETECTIVE trial.
@en
P2093
P2860
P50
P1433
P1476
Tafenoquine treatment of Plasm ...... n the Phase 2b DETECTIVE trial
@en
P2093
Claire Beaumont
Justin A Green
Maxine Taylor
Nick Carter
Pamela L St Jean
Ronnatrai Rueangweerayut
Srivicha Krudsood
Stephan Duparc
Zhengyu Xue
P2860
P2888
P356
10.1186/S12936-016-1145-5
P577
2016-02-18T00:00:00Z
P5875
P6179
1044967247